SIRT2 and ovarian carcinoma: In W1 ovarian cancer cells, 33 evoked enhanced effects on cell viability compared to singleor combination treatment with the unconjugated Sirt2 and HDAC6 inhibitors.Thus, our dual Sirt2/HDAC6 inhibitors are highly interesting new toolsto investigate the consequences and the therapeutic potential of dualinhibition of the two tubulin deacetylases Sirt2 and HDAC6.